The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.
Patients voluntarily participated in the study and signed informed consent;
Age ≥60 years old, gender unlimited;
ECOG PS ≤2;
Expected survival ≥6 months;
Patients who did not respond to previous treatment with herombopag;
A history of allergy to thrombopoietin receptor agonist (TPO-RA) drugs;
Combined with other important organ dysfunction, such as liver and kidney failure, cardiac insufficiency, etc.
Secondary thrombocytopenia, such as rheumatic immune disease, chronic liver disease, hyperlienism, malignant hematologic disease, bone marrow hematopoietic exhaustion disease (such as AA, MDS), hereditary thrombocytopenia, CVID, drug-induced thrombocytopenia, etc.;